Pediatric Neurology Market Quadrant's Clarifi ASD and the NIH funded saliva based concussion test demonstrate a strong focus on pediatric neurodiagnostics, creating sales opportunities with pediatric hospitals, neurology clinics, sports medicine programs, and school based health services seeking early autism screening and concussion diagnostics.

Regulatory and Grants FDA EUA for the Clarifi COVID 19 test and a 2.3M NIH grant for concussion testing underscore regulatory savvy and funded R&D. These credentials can support conversations with payers, hospital systems, and public health entities about future approvals and collaborative testing programs.

Leadership Credibility Recent leadership moves and industry recognition including a new Chief Technology Officer and awards enhance credibility with academic medical centers and research partners, smoothing introductions for clinical collaborations and co development deals.

Platform Expansion The Clarifi epigenetic platform targets ASD, Parkinsons and mTBI, suggesting scalable opportunities to extend diagnostics into related neurological conditions and new use cases across pediatric and adult populations through partner led pilots.

Scale Ready Partnerships With 51 to 200 employees, annual revenue between 10 and 25 million, and a HIPAA compliant AWS tech stack, Quadrant is positioned to scale through CLIA lab partnerships, contract diagnostics, and co development collaborations with healthcare networks and research institutions.